SBC Medical's First Quarter Margins Improve; Company Announces Share Buyback Program
By Meg Flippin Benzinga
DETROIT, MICHIGAN - May 20, 2025 ( NEWMEDIAWIRE ) - SBC Medical Group Holdings Inc. (NASDAQ: SBC), the Japanese owner and operator of a chain of cosmetic surgery clinics, is in transformation mode, overhauling its pricing structure and adapting to a changing marketplace, which seems to have paid off in the company's first quarter.
For the three months ended March 31, 2025, SBC Medical reported earnings per share of $0.21, which was up 5% year-over-year. EBITDA margins were 52%, up from 46% in the year-ago first quarter.
The company, which is positioning itself as a leader in the cosmetic surgery market, ended the quarter with 251 clinics, increasing the number by 36 compared to last year's first quarter. Despite a challenging marketplace in Japan, SBC Medical was able to increase its customers in the last twelve months ending in March by 14% to 6.1 million. In a nod to the quality it offers customers at its clinics, SBC Medical also reported that 71% of customers visited franchisee clinics two or more times during the quarter.
'SBC is actively preparing for strategic expansion by enhancing its platform, optimizing its profitability structure, and stabilizing its business through revised pricing strategies and adapting to changing market dynamics,' said Yoshiyuki Aikawa, Chairman and Chief Executive Officer of SBC Medical, when reporting first quarter results. 'In the first quarter of 2025, we were pleased to see the expansion of Medical Corporations (MCs) gaining traction in our franchising, procurement and rental business segments as global demand for aesthetic medical services continued to rise.'
SBC Medical Group has been focused on expanding its MCs, which are designed to help cosmetic practitioners operate cosmetic surgery centers and at the same time adhere to regulations.
SBC Medical Overhauling For Growth
While SBC reported revenue of $47 million in the first quarter - down 14% year-over-year - the company attributed that to the discontinuation of its staffing business and the divestitures of Sky Net Academy and SBC Kijimadaira Resort. Despite that, margins increased, and net income increased 15% year-over-year. 'As we move ahead, we remain confident in our ability to build a scalable franchise model while accelerating expansion across domestic and international markets, driving long-term value for shareholders and positioning the Company to capitalize on future opportunities,' said Aikawa.
SBC Medical is working hard to position itself as a leader in the cosmetic surgery market, and it isn't resting on its laurels. To address competition and keep its leading position in the industry, the company is pursuing two strategies: expanding the market by making aesthetic medicine more accessible and appealing to the masses and differentiating itself from the competition by offering advanced treatments and better pricing - bringing its treatments to the U.S. and Singapore. The company is preparing for expansion and says its first quarter results are evidence of that.
Buying Back Shares
The company underscored its confidence in its growth plan by announcing its board has approved a share buyback program of up to $5 million worth of shares. The buyback program will kick off on May 20, 2025, and last through May 20, 2026.
The company is using excess cash and future free cash flow to buy back the shares. SBC Medical said it launched the program because it believes the stock at the current share price undervalues its business performance, growth potential and the aesthetic medical market, including SBC Medical's position. The global cosmetic surgery and procedure market was worth $122.08 billion in 2022, and it is expected to grow at a CAGR of 14.7% from 2023 to 2030.
SBC Medical will buy the shares on the open market at prevailing market prices and will continue to look at other ways to enhance the liquidity of its shares. It also plans to issue shares as future stock-based compensation in proportion to the number of repurchased shares. In addition to the repurchase program, SBC Medical says it will continue to consider dividend distributions with the goal of improving its total shareholder return.
From expanding the number of clinics to overhauling its pricing to lure new customers and repeat business, SBC Medical is positioning itself to capitalize on what it expects to be growth in the aesthetic medicine market. With a new stock buyback program underway, SBC Medical is showing the world and its investors it has confidence in its growth plans.
Featured image sourced fromShutterstock.
This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice.
This content was originallypublished on Benzinga.Read further disclosureshere.
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
42 minutes ago
- Business Insider
Upcoming Stock Splits This Week (June 30 to July 4)
These are the upcoming stock splits for the week of June 30 to July 4, based on TipRanks' Stock Splits Calendar. In simple terms, a stock split boosts the number of outstanding shares by issuing more to current shareholders, while keeping the company's overall market value intact. This maneuver lowers the share price, often making the stock more affordable, and therefore more appealing, to everyday investors. Don't Miss TipRanks' Half Year Sale Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. On the flip side, some companies choose a reverse stock split, merging shares rather than dividing them. This trims the total share count while raising the price per share, again without changing the company's total market worth. Reverse splits are frequently used to meet minimum price requirements on exchanges like the Nasdaq and help avoid delisting. Whether aiming to attract more investors or stay in good standing with exchanges, these corporate moves can send important signals that investors watch closely. Let's take a look at the upcoming stock splits for the week. Ainos (AIMD) – Ainos is a dual-platform AI and biotech company, developing the 'AI Nose' scent digitization platform alongside oral interferon therapeutics for rare and autoimmune diseases. On June 26, Ainos announced a 1‑for‑5 reverse stock split, aiming to lift its share price above Nasdaq's minimum. The split will take effect at market open on June 30. Helius Medical Technologies (HSDT) – Helius Medical Technologies, known for its innovative neuromodulation devices like the PoNS® platform for neurological recovery, announced a 1-for-50 reverse stock split on June 27 to maintain compliance with Nasdaq listing requirements. The split will take effect on June 30, with Helius shares set to trade on a split-adjusted basis starting July 1. APi Group (APG) – APi Group specializes in safety, specialty, and industrial services. On May 21, APG announced a 3‑for‑2 forward stock split, conceived to lower per‑share price, increase retail access, and improve liquidity. The ex‑date is July 1, with adjusted trading beginning that day. Channel Therapeutics (CHRO) – Channel Therapeutics is a pain‑treatment biotech preparing for a merger with Pelthos Therapeutics and a NYSE American uplist. On June 27, the company announced a 10‑for‑1 reverse split to comply with listing standards and support a $50 million private placement. The split is effective before market open July 1, with split‑adjusted trading under 'Pelthos Therapeutics' starting July 2. SciSparc (SPRC) – Tel Aviv–based SciSparc, a clinical-stage developer of central nervous system therapies, announced on June 24 a 1-for-21 reverse share split to raise its share price and maintain compliance with Nasdaq listing standards. The split will take effect at market open on July 3. TipRanks Stock Splits Calendar.
Yahoo
an hour ago
- Yahoo
Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half?
Tech stocks known as the "Magnificent Seven" led market gains last year. One particular AI leader rose 800% over three years but still has plenty of room to run. 10 stocks we like better than Nvidia › A group of technology stocks, known as the "Magnificent Seven" -- a nod to the 1960 Western -- led stock market gains last year and has started to rebound in recent times. Which one makes the best buy for the second half? The answer to that question is Nvidia (NASDAQ: NVDA), even though the stock has already climbed 800% over the past three years. Let's find out why this top artificial intelligence (AI) stock may still be in the early days of its growth story. Nvidia has played a key role since the first days of the AI boom, and this is because it designs the crucial element that makes AI work: chips. They're known as graphics processing units (GPUs), and they power the fundamental step of training AI models, a process that allows those models to then handle complex tasks and solve real-world problems. So, without these chips, we wouldn't have AI. This helped Nvidia's revenue take off a few years ago, as you can see in the chart below. In Nvidia's earlier days, it primarily served the video gaming market, which resulted in progressive growth, but revenue levels were a far cry from today's AI-driven revenue. This is because companies realize the potential of this technology to save them time and money and even help them develop game-changing products and services, so they're pouring investment into AI. And Nvidia, as the leading chip designer, is benefiting. This potential is further illustrated by forecasts calling for the AI market to reach into the trillions of dollars in a few years from now. Importantly, Nvidia isn't just about GPUs. The company has built an AI empire, creating software and networking tools, and it even aims to power the humanoid robots of tomorrow. This expansion is key to Nvidia's growth because it enables the company to benefit from every stage of AI development -- not just the early days of infrastructure ramp-up. Meanwhile, Nvidia has also put the focus on innovation to ensure it stays ahead of its rivals. It has pledged to update its chips yearly and has already offered investors visibility into planned launches over the coming three years. Though rivals are carving out market share -- for example, Advanced Micro Devices recently reported a 57% increase in data center quarterly revenue -- Nvidia's innovation should keep it in the top spot. The enormous demand for AI means that others, like AMD, can succeed without truly encroaching on Nvidia's territory. The biggest disappointment for Nvidia and investors at this point (and possibly into the future) is the situation concerning exports to China. The U.S. has blocked chip exports, cutting Nvidia out of the market that represented 13% of its revenue last year. This isn't a non-event, and if the situation remains as is, it limits Nvidia's growth opportunities to some degree. The good news is that Nvidia makes most of its revenue in the U.S. and a great deal in other locations as well, so the export situation doesn't necessarily translate to slow growth for this chip giant. All this sounds positive, but why is Nvidia the best Magnificent Seven buy for the second half? Nvidia remains the best overall AI bet due to its deep presence across every stage of the technology's growth. The world's biggest tech companies turn to Nvidia to power their platforms, and that's unlikely to change, as these customers aim to use the fastest processors available -- and those are likely to have the name Nvidia on them well into the future. Nvidia will accompany these customers as they deploy AI agents within their businesses or develop humanoid robots down the road. At the same time, Nvidia's valuation leaves the stock plenty of room to run. Though it's inched higher in recent weeks, it still trades significantly lower than it did just a few months ago, at 36 times forward earnings estimates compared to more than 50 times. All these elements, from Nvidia's presence across AI to its price today, support my prediction that this stock will roar higher in the second half and over the long run, too. Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices and Nvidia. The Motley Fool has a disclosure policy. Which "Magnificent Seven" Stock Makes the Best Buy for the Second Half? was originally published by The Motley Fool Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
an hour ago
- Yahoo
Should You Buy Lucid Stock While It's Below $3?
The electric vehicle industry is facing significant headwinds right now. Lucid's vehicles are expensive, and leadership stability is a big question mark. It's best to take a wait-and-see approach to Lucid stock rather than buying. 10 stocks we like better than Lucid Group › The electric vehicle industry is enticing because, despite some setbacks, many countries and customers around the world are shifting their attention to EVs. The gains in EV adoption are often attributed to both consumer interest and government incentives that spur industry growth. The result is that in 2024, there were 1.3 million EVs sold, an increase of 7% compared to the previous year. Still, it's not all sunshine and rainbows in the EV industry. The high cost of electric vehicles and lagging EV infrastructure are cited by consumers as a significant barrier to buying an electric vehicle. Lucid (NASDAQ: LCID) knows the struggle of getting EVs off the ground in the U.S. just as well as anyone. After years of slower-than-expected production and several changes in leadership, Lucid stock has plummeted. Shares are down about 50% from their 52-week high, putting its share price under $3 right now. With the steep decline, is now a good time to buy Lucid stock at a discount? I think investors are better off waiting to see how things shake out for the company. Here's why it's better not to buy Lucid right now. Having a long-term perspective about the stocks you own is an important investment strategy, which is why it's troubling to see the U.S. backing away from some of its EV infrastructure investments and incentives. First, the Trump administration has thrown cold water on the idea of keeping tax incentives for buying electric vehicles. The incentives were worth up to $7,500 for new vehicles, and while Lucid didn't qualify for them -- its EVs are too expensive -- the incentives still acted as a catalyst to boost the broader EV industry. With those going away, there's less incentive for buyers to purchase EVs and less incentive for automakers to make bold transitions to electrified models. Additionally, the administration has walked back the government's previous commitment to invest billions of dollars in EV charging infrastructure. A legal battle over the funding is underway, but if the administration gets its way, states may not receive the $5 billion in funding to build EV chargers across the country. Broad EV market conditions matter to Lucid because it's still a fledgling EV brand. In order to succeed, Lucid and its peers need high demand for their vehicles and a larger EV charging infrastructure in place. Unfortunately, that now looks less likely over the next few years. Of course, not all of Lucid's problems stem from outside forces. One problem Lucid is currently facing is that its vehicles are just too dang expensive for many American buyers. That's not only hurting Lucid's ability to expand its customer base, but it's also hurting its ability to scale its manufacturing more efficiently. To make a profit in the auto industry, companies need to have economies of scale for their product lineups, sharing components across many vehicles. Lucid's cheapest Air sedan starts at nearly $70,000, and its Gravity SUV starts at about $80,000. The Gravity is still in low production, so any cost savings by sharing parts haven't had time to kick in yet. More importantly, the Air and Gravity starting prices are expensive by even EV standards. The average transaction price for an EV in the U.S. in May was about $57,700. That makes the cheapest Air model 21% above the average EV price, and the Gravity 39% more expensive than the average. Lucid is expected to launch its Earth EV, priced around $48,000, in 2027 or 2028. This will eventually help Lucid to achieve more efficient production costs and potentially widen its customer base, but how well the company will be able to deliver on this and when the Earth actually goes on sale are big unknowns. It was just four months ago that Peter Rawlinson stepped down from the CEO position at Lucid. The company's COO, Marc Winterhoff, is now the interim CEO as the board searches for a permanent leader. While it may have been the right move for Lucid to look for new leadership, the fact that the company is still in the process of finding a permanent replacement at such a difficult time for Lucid means investors should probably be cautious about jumping in with Lucid right now. Leadership change can be normal, but Lucid is currently on its third CEO -- two permanent and one interim -- since 2019. I'd like to see more stability in the C-suite before I feel comfortable that Lucid is on the right track and able to deliver on its EV ambitions. I'm rooting for Lucid just as I am for many EV companies, but that doesn't mean I'd feel comfortable buying its stock right now. For all the reasons above, I think it's best to take a wait-and-see approach with Lucid before buying shares. Before you buy stock in Lucid Group, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Lucid Group wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $713,547!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $966,931!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 177% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 23, 2025 Chris Neiger has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Should You Buy Lucid Stock While It's Below $3? was originally published by The Motley Fool
